Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens

Trial Profile

Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacteraemia; Gram-positive infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vicuron Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2017 Results of pooled analysis of clearance of bacteraemia data fro four phase III stuadies and a phase II study including this study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 16 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top